For the third quarter of 2026, analysts expect Neumora Therapeutics to report zero revenue and a consensus loss of $0.19 per share, as the stock currently trades at approximately $0.37 against an average price target of $6.33. Investors are primarily focused on the company’s remaining cash runway and pipeline progress following the major clinical failure and discontinuation of its former lead asset, navacaprant, in June 2026.
The report serves as a critical update on the company's survival strategy, following a 35% workforce reduction designed to preserve capital. Market attention is now centered on the development of NMRA-511 for Alzheimer's agitation and the recently submitted IND for NMRA-215 in obesity as the firm seeks new clinical catalysts to stabilize its valuation.